The hepatitis B vaccine is one of the few shots given within hours of birth, and the reason is simple: infants who catch the virus are the most likely to develop lifelong infection. A modeling study published in Annals of Internal Medicine on Oct. 20 asks what would happen if that first dose stopped being universal. Its answer, under the policy the federal government has moved toward, is an 83% rise in chronic infections among US children.

The authors are careful to call it a projection. The size of the number is still the main reason it drew attention.

What the Model Compared

The study, released by the American College of Physicians, compared three ways of vaccinating babies whose mothers tested negative for hepatitis B during pregnancy. In the first, every newborn gets a birth dose, the long-standing approach. In the second, the first dose is deferred to 2 months. In the third, parents and clinicians decide together whether to give the birth dose, known as shared clinical decision-making, which matches changes the federal government recommended this year, according to the Newswise summary.

The authors built a Markov model, a type of simulation that follows groups of people through health states over time. It tracked chronic hepatitis B infections acquired by age 20 in the 2026 birth cohort.

The Numbers

Under universal birth-dose vaccination, the model projects 255 chronic childhood infections in the 2026 birth cohort, with an uncertainty interval of 130 to 530. Deferring the first dose to 2 months raises that to 303 (155 to 610), a 19% increase. Shared decision-making raises it to 467 (209 to 1,032), an 83% increase, according to the study abstract.

Shared decision-making would also leave 50% to 70% of children entering adulthood each year susceptible to hepatitis B, the authors report. They conclude that universal birth-dose vaccination remained the most effective strategy and that policymakers should reinstate recommendations for it.

A Healthline summary reported a broader range, 83% to 225%, depending on how many families take up the vaccine, which reflects the study's sensitivity analyses. I could not verify that range in the abstract.

Why the Birth Dose Matters

Hepatitis B can pass from mother to baby at birth, and infants infected at that age are far more likely to become chronic carriers than older children or adults. The first dose within about a day of birth is meant to prevent that. A review of one country's birth-dose program, for instance, cites 90% effectiveness for preventing perinatal transmission when the first dose comes within 24 hours, followed by the remaining doses.

Doctors also worry about completion. Medical Daily reported that physicians warn that delaying the first dose can make it harder for some children to finish the full vaccine series, which is what provides long-term protection.

What the Model Cannot Say

This is a projection, and Medical Daily's summary notes that it does not prove infections will rise by these amounts. The result depends on assumptions about how many families would choose the birth dose, how many mothers have undiagnosed infections, and how many children would catch up later. The uncertainty intervals are wide: under shared decision-making, the plausible range runs from slightly below the universal-vaccination estimate to about four times it.

I did not find a response from the Department of Health and Human Services in the sources I reviewed.

Other Analyses Point the Same Way

The Annals paper is not the first. A study in JAMA Pediatrics in late April projected hundreds of additional chronic infections each year if the birth dose were delayed or omitted, Healthline said. Another analysis estimated that delaying the first dose by two months would add about $16.4 million in health care spending on new infections, even if every child eventually received the vaccine, Medical Daily reported.

Healthline said that, under the direction of Health Secretary Robert F. Kennedy Jr., the Centers for Disease Control and Prevention ended its universal recommendation for newborn hepatitis B vaccination in late 2025. That is the policy these models test.

What to Watch Next

The questions now are practical ones. Do hospitals and clinics keep offering the birth dose as a default, and how many parents choose it when given the option? Actual vaccination rates will be the real test of the models, and they will take time to measure.

The disease itself is a reminder of the stakes. Blogerroom recently reported on the FDA's approval of Hibsago, the first RNA-targeting hepatitis B drug, which cured 19% of trial patients and left 81% still infected. A treatment that works for a minority makes prevention look even more valuable. It also echoes the lesson of the US measles surge past 4,000 cases, where falling vaccination rates have had direct consequences.

Parents with questions about the hepatitis B vaccine for a newborn should talk with their pediatrician or obstetric provider. This article is general information, not medical advice.